Article
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Investigational new drugs - 1 Apr 2016
Deming Dustin A, Cavalcante Ludmila L, Lubner Sam J, Mulkerin Daniel L, LoConte Noelle K, Eickhoff Jens C, Kolesar Jill M, Fioravanti Suzanne, Greten Tim F, Compton Kathryn, Doyle Austin G, Wilding George, Duffy Austin, Liu Glenn
Abstract excerpt
BACKGROUND: KRAS mutations are clinically important predictors of resistance to EGFR-directed therapies in colorectal cancer (CRC). Oncogenic activation of the RAS/RAF/MEK/ERK signaling cascade mediates proliferation independent of growth factor signaling. We hypothesized that targeting MEK with selumetinib could overcome resistance to cetuximab in KRAS mutant CRC. METHODS: A phase I study (NCT01287130) was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.